title: Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.
abstract: To assess the extent of enterohepatic recycling of piroxicam and tenoxicam, their pharmacokinetics have been compared in the absence and presence of concomitant treatment with cholestyramine. In a randomized crossover study 6 healthy volunteers received piroxicam and tenoxicam 20 mg p.o., alone or with cholestyramine 24 g/day for 4 days. Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively). It also increased the apparent clearance (Cl/f) of piroxicam and tenoxicam by 58% and 112%. When cholestyramine was administered, the t 1/2 of piroxicam & tenoxicam were correlated (r = 0.89), which suggests that their hepatic biotransformation is under a common control. It is concluded that: piroxicam and tenoxicam are eliminated to a large and comparable extent through the biliary route, and the administration of cholestyramine may help to accelerate their elimination in cases of overdosage.
authors.affiliation: Department of Medicine, University Hospital, Geneva, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Benveniste
authors.forename: R
authors.initials: R
authors.lastname: Striberni
authors.forename: P
authors.initials: P
authors.lastname: Dayer
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D001646:Bile / Q000378:metabolism; D001711:Biotransformation; D004764:Enterohepatic Circulation; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008297:Male; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D011897:Random Allocation
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C032801:tenoxicam